Literature DB >> 26976644

The Endothelial Prolyl-4-Hydroxylase Domain 2/Hypoxia-Inducible Factor 2 Axis Regulates Pulmonary Artery Pressure in Mice.

Pinelopi P Kapitsinou1, Ganeshkumar Rajendran2, Lindsay Astleford2, Mark Michael3, Michael P Schonfeld2, Timothy Fields4, Sheila Shay3, Jaketa L French3, James West3, Volker H Haase5.   

Abstract

Hypoxia-inducible factors 1 and 2 (HIF-1 and -2) control oxygen supply to tissues by regulating erythropoiesis, angiogenesis and vascular homeostasis. HIFs are regulated in response to oxygen availability by prolyl-4-hydroxylase domain (PHD) proteins, with PHD2 being the main oxygen sensor that controls HIF activity under normoxia. In this study, we used a genetic approach to investigate the endothelial PHD2/HIF axis in the regulation of vascular function. We found that inactivation of Phd2 in endothelial cells specifically resulted in severe pulmonary hypertension (∼118% increase in right ventricular systolic pressure) but not polycythemia and was associated with abnormal muscularization of peripheral pulmonary arteries and right ventricular hypertrophy. Concurrent inactivation of either Hif1a or Hif2a in endothelial cell-specific Phd2 mutants demonstrated that the development of pulmonary hypertension was dependent on HIF-2α but not HIF-1α. Furthermore, endothelial HIF-2α was required for the development of increased pulmonary artery pressures in a model of pulmonary hypertension induced by chronic hypoxia. We propose that these HIF-2-dependent effects are partially due to increased expression of vasoconstrictor molecule endothelin 1 and a concomitant decrease in vasodilatory apelin receptor signaling. Taken together, our data identify endothelial HIF-2 as a key transcription factor in the pathogenesis of pulmonary hypertension.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26976644      PMCID: PMC4859687          DOI: 10.1128/MCB.01055-15

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  57 in total

1.  Regulation of endothelin-1 gene expression in human microvascular endothelial cells by hypoxia and cobalt: role of hypoxia responsive element.

Authors:  A Minchenko; J Caro
Journal:  Mol Cell Biochem       Date:  2000-05       Impact factor: 3.396

2.  Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension.

Authors:  Suparna M Chandra; Hedi Razavi; Jongmin Kim; Rani Agrawal; Ramendra K Kundu; Vinicio de Jesus Perez; Roham T Zamanian; Thomas Quertermous; Hyung J Chun
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-01-13       Impact factor: 8.311

3.  Hypoxia and proinflammatory factors upregulate apelin receptor expression in human stellate cells and hepatocytes.

Authors:  Pedro Melgar-Lesmes; Montserrat Pauta; Vedrana Reichenbach; Gregori Casals; Josefa Ros; Ramon Bataller; Manuel Morales-Ruiz; Wladimiro Jiménez
Journal:  Gut       Date:  2011-03-29       Impact factor: 23.059

4.  Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis.

Authors:  R M Tuder; M Chacon; L Alger; J Wang; L Taraseviciene-Stewart; Y Kasahara; C D Cool; A E Bishop; M Geraci; G L Semenza; M Yacoub; J M Polak; N F Voelkel
Journal:  J Pathol       Date:  2001-10       Impact factor: 7.996

Review 5.  Novel roles of hypoxia response system in glucose metabolism and obesity.

Authors:  Toshihiro Ichiki; Kenji Sunagawa
Journal:  Trends Cardiovasc Med       Date:  2014-03-30       Impact factor: 6.677

6.  HIF-1 regulates hypoxia- and insulin-induced expression of apelin in adipocytes.

Authors:  Alexander J Glassford; Patrick Yue; Ahmad Y Sheikh; Hyung J Chun; Shirin Zarafshar; Denise A Chan; Gerald M Reaven; Thomas Quertermous; Philip S Tsao
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-09-18       Impact factor: 4.310

7.  Pulmonary apelin levels and effects in rats with hypoxic pulmonary hypertension.

Authors:  C U Andersen; L H Markvardsen; O Hilberg; U Simonsen
Journal:  Respir Med       Date:  2009-06-17       Impact factor: 3.415

8.  Allosteric inhibition of hypoxia inducible factor-2 with small molecules.

Authors:  Thomas H Scheuermann; Qiming Li; He-Wen Ma; Jason Key; Lei Zhang; Rui Chen; Joseph A Garcia; Jacinth Naidoo; Jamie Longgood; Doug E Frantz; Uttam K Tambar; Kevin H Gardner; Richard K Bruick
Journal:  Nat Chem Biol       Date:  2013-02-24       Impact factor: 15.040

9.  Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic success.

Authors:  Cristina Branco-Price; Na Zhang; Moritz Schnelle; Colin Evans; Dörthe M Katschinski; Debbie Liao; Lesley Ellies; Randall S Johnson
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

Review 10.  Human high-altitude adaptation: forward genetics meets the HIF pathway.

Authors:  Abigail W Bigham; Frank S Lee
Journal:  Genes Dev       Date:  2014-10-15       Impact factor: 11.361

View more
  63 in total

Review 1.  Discovery of a murine model of clinical PAH: Mission impossible?

Authors:  Zhiyu Dai; You-Yang Zhao
Journal:  Trends Cardiovasc Med       Date:  2016-12-15       Impact factor: 6.677

2.  Endothelial prolyl hydroxylase 2 is necessary for angiotensin II-mediated renal fibrosis and injury.

Authors:  Yongzhen Zhao; Heng Zeng; Bo Liu; Xiaochen He; Jian-Xiong Chen
Journal:  Am J Physiol Renal Physiol       Date:  2020-07-27

Review 3.  Cellular Pathways Promoting Pulmonary Vascular Remodeling by Hypoxia.

Authors:  Larissa A Shimoda
Journal:  Physiology (Bethesda)       Date:  2020-07-01

4.  Modulation of Intersectin-1s Lung Expression Induces Obliterative Remodeling and Severe Plexiform Arteriopathy in the Murine Pulmonary Vascular Bed.

Authors:  Monal Patel; Dan Predescu; Cristina Bardita; Jiwang Chen; Niranjan Jeganathan; Melanie Pritchard; Salvatore DiBartolo; Roberto Machado; Sanda Predescu
Journal:  Am J Pathol       Date:  2017-01-06       Impact factor: 4.307

Review 5.  Transcription factors, transcriptional coregulators, and epigenetic modulation in the control of pulmonary vascular cell phenotype: therapeutic implications for pulmonary hypertension (2015 Grover Conference series).

Authors:  Soni S Pullamsetti; Frédéric Perros; Prakash Chelladurai; Jason Yuan; Kurt Stenmark
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

6.  Endothelial Hypoxia-Inducible Factor-2α Is Required for the Maintenance of Airway Microvasculature.

Authors:  Xinguo Jiang; Wen Tian; Allen B Tu; Shravani Pasupneti; Eric Shuffle; Petra Dahms; Patrick Zhang; Haoliang Cai; Thanh T Dinh; Bo Liu; Corey Cain; Amato J Giaccia; Eugene C Butcher; M Celeste Simon; Gregg L Semenza; Mark R Nicolls
Journal:  Circulation       Date:  2019-01-22       Impact factor: 29.690

Review 7.  Hypoxia-inducible factor signaling in pulmonary hypertension.

Authors:  Soni Savai Pullamsetti; Argen Mamazhakypov; Norbert Weissmann; Werner Seeger; Rajkumar Savai
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

Review 8.  The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

Authors:  Thomas Bertero; Dror Perk; Stephen Y Chan
Journal:  Expert Opin Ther Targets       Date:  2019-05-11       Impact factor: 6.902

9.  Divergent changes of p53 in pulmonary arterial endothelial and smooth muscle cells involved in the development of pulmonary hypertension.

Authors:  Ziyi Wang; Kai Yang; Qiuyu Zheng; Chenting Zhang; Haiyang Tang; Aleksandra Babicheva; Qian Jiang; Meichan Li; Yuqin Chen; Shane G Carr; Kang Wu; Qian Zhang; Angela Balistrieri; Christina Wang; Shanshan Song; Ramon J Ayon; Ankit A Desai; Stephen M Black; Joe G N Garcia; Ayako Makino; Jason X-J Yuan; Wenju Lu; Jian Wang
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-25       Impact factor: 5.464

Review 10.  Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD.

Authors:  Sophie Van Welden; Andrew C Selfridge; Pieter Hindryckx
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-30       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.